Crizotinib

Crizotinib Reactions 1704, p122 - 2 Jun 2018 Emesis and visual disorders: case report In a retrospective analysis involving 38 patients, one female patient [age not stated] was described, who developed emesis and visual disorders during treatment with crizotinib [duration of treatment to reactions onsets and outcomes not stated]. The female patient, who was diagnosed with inflammatory myofibroblastic tumors at the age of 10.6 years, received multiple chemotherapies followed by subsequent systemic therapy comprising of crizotinib [route and dosage not stated]. Her tumour responded to crizotinib treatment, but she developed emesis and visual disorders as side effects of crizotinib therapy. The patient did not report therapy related toxicities after the reduction of the crizotinib dose. About 1 year after the crizotinib treatment, her parents stopped the treatment, but it was continued again after a 2 month gap due to progression of disease. Author comment: "Due to the fact that the treatment period of our analysis was mainly before the approval of [anaplastic lymphoma kinase] inhibitors, only one patient received therapy with the [anaplastic lymphoma kinase] inhibitor crizotinib." "The tumor responded to crizotinib but the patient suffered side effects (emesis, visual disorders)." Kube S, et al. Inflammatory myofibroblastic tumors-A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe. Pediatric Blood and Cancer 65: e27012, No. 6, Jun 2018. Available from: URL: http://doi.org/10.1002/pbc.27012 - Germany 803324062 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Crizotinib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/crizotinib-uH7sSffXy9
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46765-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p122 - 2 Jun 2018 Emesis and visual disorders: case report In a retrospective analysis involving 38 patients, one female patient [age not stated] was described, who developed emesis and visual disorders during treatment with crizotinib [duration of treatment to reactions onsets and outcomes not stated]. The female patient, who was diagnosed with inflammatory myofibroblastic tumors at the age of 10.6 years, received multiple chemotherapies followed by subsequent systemic therapy comprising of crizotinib [route and dosage not stated]. Her tumour responded to crizotinib treatment, but she developed emesis and visual disorders as side effects of crizotinib therapy. The patient did not report therapy related toxicities after the reduction of the crizotinib dose. About 1 year after the crizotinib treatment, her parents stopped the treatment, but it was continued again after a 2 month gap due to progression of disease. Author comment: "Due to the fact that the treatment period of our analysis was mainly before the approval of [anaplastic lymphoma kinase] inhibitors, only one patient received therapy with the [anaplastic lymphoma kinase] inhibitor crizotinib." "The tumor responded to crizotinib but the patient suffered side effects (emesis, visual disorders)." Kube S, et al. Inflammatory myofibroblastic tumors-A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe. Pediatric Blood and Cancer 65: e27012, No. 6, Jun 2018. Available from: URL: http://doi.org/10.1002/pbc.27012 - Germany 803324062 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off